TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10211538
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide 300 and 500 microg twice daily
Study: 10211538
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone 10 mg every morning
Study: 10211538
Drug: Flunisolide 500
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flunisolide 500 microg twice daily
Study: 10211538
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide 500 microg twice daily
Study: 8687088
Drug: AO/ASIF implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: AO/ASIF implants
Study: 8687088
Drug: Non‐operative treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐operative treatment
Study: 2087015
Drug: AS‐4370 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS‐4370 2.5 mg
Study: 2087015
Drug: AS‐4370 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS‐4370 5 mg
Study: 2087015
Drug: AS‐4370 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS‐4370 10 mg
Study: 6819596
Drug: Fluvoxamine (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (150-300 mg per day)
Study: 6819596
Drug: Chlorimipramine (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorimipramine (150-300 mg per day)
Study: 31585522
Drug: Information about
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information about treatment
Study: 26982446
Drug: Text messaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text messaging intervention for medication adherence or symptom severity
Study: 19703761
Drug: GLA+prandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GLA+prandial insulin lispro (LIS)
Study: 19703761
Drug: GLA+prandial regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLA+prandial regular human insulin (RHI)
Study: 19703761
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (LIS and RHI)
Study: 16327946
Drug: Oral Pycnogenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Pycnogenol
Study: 16327946
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (oral and local)
Study: 2239719
Drug: Triglyceride fish
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglyceride fish oil (6 g/day)
Study: 2239719
Drug: Ethyl ester
Normalized name: Amben ethyl ester
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethyl ester fish oil (7 g/day)
Study: 2239719
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (12 g/day)
Study: 31842993
Drug: 3-day treatment
Normalized name: Gyne-Lotrimin 2% 3-Day Treatment Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day treatment with 40 mg prednisone daily followed by 2 days of placebo (experimental arm, n = 235)
Study: 31842993
Drug: 5-day treatment
Normalized name: 30 day Acne Treatment Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day treatment with 40 mg prednisone daily (conventional arm, n = 235)
Study: 26414337
Drug: Varenicline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (2 mg daily, titrated from 0.5 mg during first week)
Study: 22392603
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral iron therapy
Study: 22392603
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly oral iron therapy
Study: 22392603
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly oral iron therapy
Study: 19770129
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) 80 mg/m² on day 1 and irinotecan 60 mg/m² on days 1 and 8 followed by accelerated hyperfractionated thoracic radiotherapy (60 Gy/40 fractions in 4 weeks) with daily carboplatin (CBDCA) administration.
Study: 19770129
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) and irinotecan chemotherapy followed by radiotherapy with daily carboplatin.
Study: 14724304
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of albendazole per day and 6 mg of dexamethasone per day for 10 days
Study: 9498726
Drug: Sertindole 12
Normalized name: sertindole 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole 12 mg daily with alprazolam 1 mg
Study: 7620470
Drug: Behavioral family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral family systems therapy (BFST)
Study: 31846795
Drug: Antibiotics in
Normalized name: Other cytotoxic antibiotics in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics in the first week of life
Study: 30040523
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (arm A)
Study: 30040523
Drug: Bevacizumab during
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab during AC and paclitaxel followed by bevacizumab monotherapy for 10 cycles (arm C)
Study: 19923501
Drug: 1500 mL
Normalized name: Bag/Pump Set 1500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mL of 6% HES 130/0.42 in a balanced electrolyte solution (n = 25)
Study: 19923501
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of 5% human albumin plus 1000 mL 0.9% saline solution (n = 25)
Study: 2974791
Drug: DianeR (cyproterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: DianeR (cyproterone acetate 2 mg and ethinylestradiol 50 micrograms per pill - D-50)
Study: 2974791
Drug: Diane 35
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane 35 (cyproterone acetate 2 mg and ethinylestradiol 35 micrograms per pill - D-35)
Study: 24656555
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of sc DMPA 104 mg
Study: 24656555
Drug: Clinician administration
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician administration of sc DMPA 104 mg
Study: 15864235
Drug: ezetimibe/simvastatin (10/10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin (10/10, 10/20, 10/40, or 10/80 mg)
Study: 15864235
Drug: ezetimibe/simvastatin (10/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin (10/40 and 10/80 mg)
Study: 15864235
Drug: atorvastatin (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin (10, 20, 40, or 80 mg)
Study: 8852908
Drug: Aerosolized human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized human IgG (Sandoglobulin) at a dose of 0.1 g/kg in a 5% solution, delivered in 2 parts on the day of hospital admission.
Study: 8852908
Drug: Placebo, identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, identical amount as the treatment group, delivered in 2 parts on the day of hospital admission.
Study: 2880743
Drug: Lysine acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetylsalicylate (LAS) infusion (66 mg/min for 120 min)
Study: 2880743
Drug: Somatostatin (SRIF)
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (SRIF) infusion (150 micrograms bolus followed by 100 micrograms/h for 120 min)
Study: 2880743
Drug: Arginine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginine (25 g i.v. in 30 min)
Study: 2880743
Drug: Lysine acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetylsalicylate (LAS) infusion
Study: 26384407
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO3) ingestion (0.4 g/kg body weight)
Study: 29193741
Drug: High-fructose corn
Normalized name: High Fructose Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fructose corn syrup (HFCS)
Study: 19090341
Drug: CLIN/RA gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLIN/RA gel (clindamycin phosphate 1.2%-tretinoin 0.025%)
Study: 12701861
Drug: Prophylactic intravitreal
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic intravitreal injection of vancomycin 1 mg and ceftazidime 2.25 mg
Study: 12701861
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no prophylactic intravitreal antibiotics)
Study: 1329475
Drug: Lisinopril (2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (2.5-10 mg once daily)
Study: 4054521
Drug: Ileal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ileal infusion of lipid emulsion (50% corn oil, 3% albumen)
Study: 4054521
Drug: Control infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control infusion of albumen and saline
Study: 4054521
Drug: Ileal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ileal infusion of corn oil emulsions
Study: 4054521
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of fat emulsion
Study: 4054521
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of isosmotic saline
Study: 22727177
Drug: Low-dose fluocinolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fluocinolone acetonide insert (0.2 μg/d)
Study: 22727177
Drug: High-dose fluocinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fluocinolone acetonide insert (0.5 μg/d)
Study: 20214164
Drug: Intralesional sodium
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intralesional sodium chloride hypertonic solution (7%)
Study: 10530579
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (CAE) 30 mg/kg/day in two divided doses for 5 days
Study: 10530579
Drug: Amoxicillin/clavulanate (A/CA-10)
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (A/CA-10) 40 mg/kg/day in three divided doses for 10 days
Study: 10530579
Drug: Amoxicillin/clavulanate (A/CA-8)
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (A/CA-8) 80 mg/kg/day in three divided doses for 8 days
Study: 7722188
Drug: Fermented soy
Normalized name: DIMETHICONE 4 g in 100 g CUTANEOUS PATCH [FERMENTED SOY MILK WRINKLE CARE SLEEPING MASK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented soy product (112 g tempeh)
Study: 7722188
Drug: Unfermented soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfermented soy (125 g soybean pieces)
Study: 1336212
Drug: Alfentanil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (100 mcg/kg i.v. and maintenance of 2-3 mcg/kg/min)
Study: 1336212
Drug: Naloxone (0.2-0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.2-0.4 mg) administered after surgery
Study: 6231418
Drug: Ampicillin administration
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin administration
Study: 6231418
Drug: Oxytetracycline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytetracycline (2 X 500 mg/day for 5 days)
Study: 6231418
Drug: Tetracycline and
Normalized name: tetracycline and nystatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline and trimethoprim administration
Study: 6231418
Drug: Antimicrobial drugs
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial drugs
Study: 26866874
Drug: Once-daily transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily transcranial direct current stimulation (tDCS) targeting left frontal and temporo-parietal areas for five days
Study: 22806212
Drug: Memantine (16-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (16-week treatment)
Study: 22806212
Drug: Placebo (16-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (16-week treatment)
Study: 2405141
Drug: Human surfactant
Normalized name: recombinant human surfactant protein D
DrugBank: Zelpultide alfa (DB18587)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human surfactant derived from amniotic fluid, administered within 12 hours of birth, with a second dose if needed.
Study: 7138738
Drug: Paracetamol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol + codeine phosphate (400 mg + 30 mg)
Study: 7138738
Drug: Plain paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain paracetamol (400 mg)
Study: 7138738
Drug: Paracetamol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (400 mg)
Study: 27535171
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (n = 29)
Study: 25164908
Drug: Experimental arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental arm (customized therapy based on BRCA1/RAP80 expression)
Study: 18712389
Drug: Level of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level of recommendation for adjuvant chemotherapy
Study: 8051620
Drug: Passive immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive immunotherapy with HIV-1 neutralizing monoclonal antibodies
Study: 24278914
Drug: Two-part implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-part implants
Study: 19839993
Drug: Asenapine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine (10 mg BID on day 1; 5 or 10 mg BID thereafter; mean daily dosage 18.2 mg)
Study: 19839993
Drug: Olanzapine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (15 mg BID on day 1; 5-20 mg QD thereafter; mean daily dosage 15.8 mg)
Study: 10913502
Drug: Lithium (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (administered for 4 weeks)
Study: 9299654
Drug: Pseudoephedrine retard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine retard (120 mg)
Study: 9299654
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cetirizine (5 mg) and pseudoephedrine retard (120 mg)
Study: 9299654
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cetirizine and pseudoephedrine
Study: 8143888
Drug: Norfloxacin, Ofloxacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin, Ofloxacin, Enoxacin, Ciprofloxacin, Lomefloxacin (200 mg three times daily for 3 consecutive days)
Study: 24742255
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (30 minutes twice weekly for 6 weeks)
Study: 24742255
Drug: Nonmassage touch/holding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmassage touch/holding sham treatment (30 minutes twice weekly for 6 weeks)
Study: 10470326
Drug: Antagonists to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antagonists to inflammatory cytokines IL-1 and TNF
Study: 31618539
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (laparoscopic Nissen fundoplication)
Study: 31618539
Drug: Active medical
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medical treatment (omeprazole plus baclofen, with desipramine added depending on symptoms)
Study: 31618539
Drug: Control medical
Normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control medical treatment (omeprazole plus placebo)
Study: 31618539
Drug: Active medical
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medical treatment
Study: 24820653
Drug: Not receiving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not receiving oral alendronate (Control)
Study: 18947980
Drug: Capsule of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule of olive leaf extract
Study: 9806313
Drug: Low energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low energy density (LED) diet (373 kJ/100 g)
Study: 9806313
Drug: Medium energy
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium energy density (MED) diet (549 kJ/100 g)
Study: 9806313
Drug: High energy
Normalized name: High energy formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energy density (HED) diet (737 kJ/100 g)
Study: 2375667
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no exercise beyond usual daily activities)
Study: 333856
Drug: Bromocriptine (2.5-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2.5-40 mg)
Study: 25785522
Drug: Modified cardiovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified cardiovascular component of the Sequential Organ Failure Assessment score
Study: 25785522
Drug: Cardiovascular component
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiovascular component of the Sequential Organ Failure Assessment score
Study: 25785522
Drug: Modified Sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Sequential Organ Failure Assessment score
Study: 25785522
Drug: Existing Sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing Sequential Organ Failure Assessment score
Study: 19221692
Drug: Huperzine A
Normalized name: Huperzine A
DrugBank: Huperzine A (DB04864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huperzine A (HupA), oral administration for 8-24 weeks at a dosage of 300-500 microg daily
Study: 15347372
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 400 microg b.i.d.
Study: 15347372
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 800 microg b.i.d.
Study: 2971564
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of Salbutamol (S) and Ipratropium bromide (IB)
Study: 25795076
Drug: MPa200Z regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPa200Z regimen (moxifloxacin, 200 mg pretomanid, and pyrazinamide)
Study: 25795076
Drug: DRMPa200Z regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRMPa200Z regimen (moxifloxacin, 200 mg pretomanid, and pyrazinamide for drug-resistant tuberculosis)
Study: 25795076
Drug: MPa100Z regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPa100Z regimen (moxifloxacin, 100 mg pretomanid, and pyrazinamide)
Study: 23698396
Drug: Lixisenatide 20
Normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 20 μg once daily
Study: 29596853
Drug: Exenatide 10
Normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 10 μg twice daily
Study: 21593296
Drug: Liraglutide plus
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide plus insulin in C‐peptide positive patients
Study: 21593296
Drug: Liraglutide plus
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide plus insulin in C‐peptide negative patients
Study: 21593296
Drug: Insulin monotherapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin monotherapy in C‐peptide negative patients
Study: 9816131
Drug: 13-cis retinoic
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 13-cis retinoic acid (13cRA) treatment for 6 months
Study: 9816131
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation during treatment
Study: 1727833
Drug: 19NT‐HPP alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19NT‐HPP alone (400 mg loading dose, followed by 200 mg every 3 weeks for 24 weeks)
Study: 1727833
Drug: 19NT‐HPP with
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19NT‐HPP with buserelin (3.3 or 6.6 mg implant after initial androgen suppression)
Study: 6421140
Drug: Flecainide, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide, 200 mg twice daily
Study: 6421140
Drug: Disopyramide, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide, 150 mg 4 times daily
Study: 31194247
Drug: Afatinib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (40 mg/d)
Study: 29902295
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg/d)
Study: 26311707
Drug: Total mastic
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total mastic (TM, n=72) receiving daily a total dose of 1 g of crude CMG (330 mg capsules, tid)
Study: 26311707
Drug: Polymer-free mastic
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymer-free mastic (PFM, n=33) receiving daily a total dose of 1 g of polymer free mastic (330 mg caps, tid)